title: Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis.
abstract: To systematically review the safety and efficacy of lenvatinib in the treatment of patients, we retrieved all the relevant clinical trials on the adverse events (AEs) and survival outcomes of lenvatinib through PubMed, Medline, Embase, Web of Science and Cochrane Collaboration's Central register of controlled trial. Fourteen eligible studies involving a total of 978 patients were included in our analysis. The most common all-grade AEs observed in patients treated with lenvatinib were hematuria (56.6%), fatigue (52.2%) and decreased appetite (50.5%). The most frequently observed grade ≥3 AEs were thrombocytopenia (25.4%), hypertension (17.7%) and edema peripheral (15.5%). The incidences of both all-grade and high-grade hypertension were significantly increased. Meanwhile, the controlled trial suggested that progression free survival (PFS) was significantly longer in the lenvatinib group than the placebo group. Subgroup analyses showed that mean PFS for renal cell carcinoma was 10.933±1.828 months (95% CI 7.350-14.515, p < 0.001), and that for thyroid cancer was 18.344±0.083 months (95% CI 18.181-18.506, p < 0.001). In conclusion, lenvatinib is an effective agent in thyroid cancer. Early monitoring and effective management of side effects are crucial for the safe use of this drug.
authors.affiliation: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, PR China.
authors.forename: Chenjing
authors.initials: C
authors.lastname: Zhu
authors.affiliation: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, PR China.
authors.forename: Xuelei
authors.initials: X
authors.lastname: Ma
authors.affiliation: West China School of Medicine, West China Hospital, Sichuan University, Chengdu 610041, PR China.
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Hu
authors.affiliation: West China School of Medicine, West China Hospital, Sichuan University, Chengdu 610041, PR China.
authors.forename: Linghong
authors.initials: L
authors.lastname: Guo
authors.affiliation: Department of Oncology, The First People's Hospital of Chengdu City, Chengdu 610041, PR China.
authors.forename: Bo
authors.initials: B
authors.lastname: Chen
authors.affiliation: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, PR China.
authors.forename: Kai
authors.initials: K
authors.lastname: Shen
authors.affiliation: West China School of Medicine, West China Hospital, Sichuan University, Chengdu 610041, PR China.
authors.forename: Yue
authors.initials: Y
authors.lastname: Xiao
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D018572:Disease-Free Survival; D005221:Fatigue / Q000139:chemically induced; D006417:Hematuria / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy*; D010671:Phenylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D011804:Quinolines; C531958:lenvatinib
keywords: cancer; efficacy; lenvatinib; meta-analysis; safety